Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428818 | 0.84 | ATM (0.46) | ATM | |
| SCHEMBL21075266 | 0.84 | ATM (0.46) | ATM | |
| SCHEMBL25335347 | 0.83 | ATM (0.33) | ATM | |
| SCHEMBL20446514 | 0.81 | HSD17B10 (0.39) | ATMCYP2C19HSD17B10 | |
| SCHEMBL15718593 | 0.81 | HSD17B10 (0.39) | ATMCYP2C19HSD17B10 | |
| SCHEMBL19066055 | 0.81 | HSD17B10 (0.39) | ATMCYP2C19HSD17B10 | |
| SCHEMBL20307078 | 0.80 | PIK3CD (0.34) | ATM | |
| SCHEMBL19075644 | 0.79 | RIPK1 (0.34) | RIPK1LMNACYP2C19HSD17B10 | |
| SCHEMBL19075530 | 0.79 | RIPK1 (0.34) | RIPK1LMNACYP2C19HSD17B10 | |
| SCHEMBL19083915 | 0.78 | HSD11B1 (0.32) | RIPK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885RIPK1 4567/4885LMNA 462/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | ATM 4395/4885RIPK1 4567/4885LMNA 462/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885RIPK1 4567/4885LMNA 462/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | ATM 4395/4885RIPK1 4567/4885LMNA 462/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885RIPK1 4567/4885LMNA 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.